Fast, Cost-Effective Single Cell RNA Sequencing

There is a growing desire to answer questions about the genome at the level of the individual cell. Single cell technologies promise to make a significant impact on research and clinical studies; however, complimentary high-throughput sequencing for these studies requires large capital expenditure and expensive consumables. The G4 Sequencing Platform addresses these challenges and enables researchers to generate low-cost, accurate scRNA-seq results with more flexibility and speed than any other sequencer on the market.

G4

Delivering Power and Flexibility for Single Cell Sequencing Labs

G4 features proprietary 4-color Rapid SBS chemistry and advanced engineering, designed to provide labs with unmatched operational efficiency and industry-leading run times.  G4 integrates seamlessly into existing NGS workflows and is well suited for single cell sequencing labs.

Key capabilities:

  • Single-day turnaround times
  • Highly accurate data
  • 1–4 flow cell, 4–16 lane run flexibility
  • Up to 3.2B paired reads per run

Highly Accurate Single Cell RNA Sequencing on the G4

  • Highly-accurate single cell data comparable to the NextSeq 2000
  • Rapid and cost-efficient sequencing of single cell RNA sequencing (scRNA-seq) libraries
  • Seamless compatibility of the G4 Sequencing Platform with 10x Genomics library preparation workflows and bioinformatics pipelines

Introducing Max Read Sequencing Kits

High throughput, low-cost single cell sequencing. 
Up to 3.2 billion paired reads per run at $1 per million reads.  

G4 Specifications for Single Cell RNA Sequencing

F2 Flow Cell F3 Flow Cell Max Read2
Paired Reads Delivered / Flow Cell 200M 400M 800M
Paired Reads Delivered / Run 800M 1.6B 3.2B
# Samples / Flow Cell1 1 2 4
# Samples / Run1 4 8 16
Price / M Paired Read $3.0 $1.8 $1.0
Run Time ~15 hours ~15 hours ~30 hours
Quality >85% bases ≥ Q30

G4 can process up to 4 flow cells in parallel. Number of reads and sequencing output shown is per flow cell.
1Assumes 28×91 read configuration, 10,000 cells/sample and 20,000 reads/cell.
2Currently only compatible with 10x Genomics Chromium™ 3’ and 5’ Gene Expression assays and Visium™ Spatial Gene Expression. Kits allow for 1 sample per lane and cannot be run at the same time as F2 or F3 flow cells.

G4 Plug-and-Play Capability

We have partnered with industry-leading library preparation providers and bioinformatic pipelines to ensure the G4 Sequencing Platform seamlessly integrates into existing NGS workflows.

Talk to an expert about Single Cell RNA Sequencing on the G4 today

Speak to a member of the Singular team to learn more about the available kits and capabilities for single cell sequencing on the G4. 

Download Single Cell RNA-Seq Application Note

Please provide your information to download the app note.

Download Parse Biosciences Application Note

Please provide your information to download the app note.

Download Single Cell Poster

Please take a moment to provide some information prior to downloading.

Download Takara Bio Application Note

Please provide your information to download the app note.

Talk to an Expert

Provide your information and a member of the Singular Genomics team will be in contact to schedule a meeting.

Download Demo Data

Please take a moment to provide some information prior to downloading.

Download Application Note

Please take a moment to provide some information prior to downloading.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note